Nev. Admin. Code § 459.300 - Specific licenses: Manufacture, preparation or transfer for commercial distribution of radioactive drugs
1. An application
for a specific license to manufacture, prepare or transfer for commercial
distribution radioactive drugs containing radioactive material for use by
persons authorized under a license issued by the Nuclear Regulatory Commission
or any other agreement state will be approved if:
(a) The applicant satisfies the general
requirements specified in NAC 459.238;
(b) The applicant submits evidence that the
applicant is:
(1) Registered or licensed as
the owner or operator of a drug establishment that engages in the manufacture,
preparation, propagation, compounding or processing of a drug by:
(I) The United States Food and Drug
Administration pursuant to
21 C.F.R. § 207.20(a); or
(II) An agency of this State pursuant to
equivalent regulations;
(2) Licensed as a pharmacy by the State Board
of Pharmacy;
(3) Operating as a
nuclear pharmacy within a medical facility; or
(4) A positron emission tomography drug
production facility licensed by or registered with a state agency;
(c) The applicant submits
information on the radionuclide, chemical and physical form, maximum activity
per vial, syringe, generator or other container of the radioactive drug and
shielding provided by the packaging of the radioactive material to demonstrate
that it is appropriate for safe handling and storage of radioactive drugs by
licensees authorized to use radioactive material for medical use; and
(d) The applicant complies with the following
labeling requirements:
(1) A label must be
affixed to each transport radiation shield of the radioactive drug, including,
without limitation, shields made of lead, glass or plastic, to be transferred
for commercial distribution. The label must set forth or contain the radiation
symbol, the words "CAUTION, RADIOACTIVE MATERIAL" or "DANGER, RADIOACTIVE
MATERIAL," the name of the radioactive drug, or its abbreviation, and the
quantity of radioactivity at the time and date specified on the label. For
radioactive drugs with a half-life of more than 100 days, the time may be
omitted from the label.
(2) A label
must be affixed to each syringe, vial or other container used to hold a
radioactive drug to be transferred for commercial distribution. The label must
set forth the radiation symbol, the words "CAUTION, RADIOACTIVE MATERIAL" or
"DANGER, RADIOACTIVE MATERIAL" and an identifier which ensures that the
syringe, vial or other container can be correlated with the information on the
transport radiation shield label.
2. A licensee who is licensed as a pharmacy
by the State Board of Pharmacy or who is operating as a nuclear pharmacy within
a medical facility:
(a) May prepare a
radioactive drug for medical use if the radioactive drug is prepared by an
authorized nuclear pharmacist as specified in paragraphs (b) and (c) or a
person under the supervision of an authorized nuclear pharmacist as defined in
10
C.F.R. §
35.27.
(b) May allow a pharmacist to work as an
authorized nuclear pharmacist if the pharmacist qualifies as an authorized
nuclear pharmacist, as defined in
10
C.F.R. §
35.2, or if the pharmacist
meets the requirements of
10 C.F.R.
§§
35.55(b) and
35.59, and
the licensee has received an approved license amendment which identifies the
pharmacist as an authorized nuclear pharmacist.
(c) May designate a pharmacist as an
authorized nuclear pharmacist if the pharmacist:
(1) Was a nuclear pharmacist preparing only
radioactive drugs containing accelerator-produced radioactive material;
and
(2) Practiced at a pharmacy at
a government agency or federally recognized Indian tribe before November 30,
2007, or at any other pharmacy before August 8, 2009, or an earlier date as
noticed by the Nuclear Regulatory Commission.
(d) Shall provide to the Division:
(1) A copy of the certification by a
specialty board whose certification process has been recognized by the Nuclear
Regulatory Commission or an agreement state as provided in
10 C.F.R. §
35.55(a) with the written
attestation signed by a preceptor as required by
10 C.F.R. §
35.55(b)(2);
(2) A copy of:
(I) The Nuclear Regulatory Commission or
agreement state license;
(II) The
Nuclear Regulatory Commission master materials licensee permit; or
(III) The permit issued by a licensee or
Nuclear Regulatory Commission master materials permittee of broad
scope;
(3) The
authorization from a commercial nuclear pharmacy that is authorized to list its
own authorized nuclear pharmacist or documentation which indicates that only
accelerator-produced radioactive materials were used in the practice of nuclear
pharmacy at a government agency or federally recognized Indian tribe before
November 30, 2007, or at all other locations of use before August 8, 2009, or
an earlier date as noticed by the Nuclear Regulatory Commission; and
(4) A copy of the license or registration of
the pharmacy or nuclear pharmacy within 30 days after the pharmacist performs
any of the activities set forth in this subsection.
3. A licensee who prepares
radioactive drugs for medical use pursuant to this section shall:
(a) Possess and use an instrument to measure
the radioactivity of alpha-, beta- or photon-emitting radioactive
drugs;
(b) Have procedures for the
use of the instrument;
(c) Measure,
by direct measurement or by a combination of measurements and calculations, the
amount of radioactivity in dosages of alpha-, beta- or photon-emitting
radioactive drugs before transfer for commercial distribution;
(d) Perform tests before initial use,
periodically and following repair on each instrument for accuracy, linearity
and geometry dependence, as appropriate for the instrument, and make
adjustments to the instrument if necessary; and
(e) Check each instrument for constancy and
proper operation at the beginning of each day of use.
4. The provisions of this section do not
relieve a licensee of his or her duty to comply with any other federal, state
or local requirement governing the receipt, administration or use of drugs or
radioactive drugs.
Notes
NRS 459.201
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.